Advanced/Metastatic Gastrointestinal Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

When gastrointestinal cancer is referred to as advanced or metastatic, it means that it has spread beyond the stomach to at least one other organ, such as the liver or lungs. A diverse, complex group of illnesses and conditions is referred to as gastrointestinal cancer. The incidence of these cancers varies greatly, with colon cancer having the highest rates in the United States, Europe, Australia, and Japan, and stomach and liver cancer having relatively high rates in Africa and Asia. Delivery of adjuvant medications to patients with locally advanced disease has made significant strides in recent years, and both perioperative chemotherapy and adjuvant chemoradiotherapy exhibit notable survival benefits. The standard of care for patients with resectable disease is being modified in light of these findings.

Description

Advanced/metastatic gastrointestinal cancer denotes the spread of the stomach-originating cancer to at least one additional body organ, such as the liver or lungs. A diverse, complex group of illnesses and conditions is referred to as gastrointestinal cancer. They can be separated into rare sporadic forms and more frequent hereditary forms. Precancerous lesions develop from normal tissue, and precancerous lesions progress to overt metastases as a result of important interactions between genetic and environmental factors. Despite the fact that certain genetic mechanisms are better understood in the context of particular cell and tissue types, there are some general similarities among gastrointestinal cancers with various etiologies. A group of cancers that affect the gastrointestinal tract collectively fall under the umbrella term of "gastrointestinal (GI) cancer.". The esophagus, liver, stomach, gallbladder, bile duct, pancreas, gastrointestinal stromal tumors (GIST), neuroendocrine tumors (NET), colorectal, small bowel, and anal are some of the cancers on this list. Abdominal pain, nauseousness, heartburn or indigestion, blood in the stool, anaemia, loss of appetite, and weight loss are a few of these symptoms. Endoscopy or colonoscopy, followed by a biopsy of tissue from the suspected site, are typically necessary for diagnosis.

Advanced/Metastatic Gastrointestinal Cancer (Epidemiology)

The incidence of these cancers varies greatly, with colon cancer having the highest rates in the United States, Europe, Australia, and Japan, and stomach and liver cancer having relatively high rates in Africa and Asia. These tumors' etiology might be influenced by environmental and genetic factors. In addition to smoking, other lifestyle elements like exposure to infections, alcohol consumption, physical activity, and diet may also have a significant impact on the development of these cancers. The second most common cause of death worldwide from all cancers is still gastric cancer (GC), which is the fourth most common malignancy overall (989,600 new cases per year in 2008). The five-year survival rate is better than 90% only in Japan. Ten% to thirty% of people survive in European nations. Early endoscopy-based diagnosis and tumor resection are likely to be the keys to Japan's high survival rates. The majority of new cases-more than 50%-occur in underdeveloped nations. The risk between the groups with the highest and lowest risks varies by 15 to 20 times. East Asia (China and Japan), Eastern Europe, as well as Central and South America, are high-risk areas. South Asia, North and East Africa, North America, Australia, and New Zealand all fall under the category of low-risk regions.

Advanced/Metastatic Gastrointestinal Cancer -Current Market Size & Forecast Trends

The market for advanced metastatic gastrointestinal cancer is projected to experience significant growth, with the metastatic cancer drugs market expected to reach approximately USD 75.05 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.6%. This growth is driven by advancements in precision medicine, biomarker-driven therapies, and the increasing incidence of gastrointestinal cancers. Specific segments, such as the gastric cancer drug market, are also expected to see substantial growth, with projections indicating a rise from USD 5.28 billion in 2024 to about USD 16.11 billion by 2032, at a CAGR of 14.95%. The overall gastrointestinal cancer market will benefit from innovations in targeted therapies and immunotherapies, improving patient outcomes and expanding treatment options. Overall, the advanced metastatic gastrointestinal cancer market is well-positioned for substantial growth through 2035 as new therapies and treatment strategies continue to emerge.

Both perioperative chemotherapy and adjuvant chemoradiotherapy exhibit notable survival benefits, and significant strides have been made in the past few years in the delivery of adjuvant medications to patients with locally advanced diseases. The standard of care for patients with resectable disease is changing as a result of these discoveries. When developing new cytotoxic regimens for patients with metastatic gastric cancer, it is important to balance efficacy and toxicity in patients who have a poor prognosis overall. The development of oral fluoropyrimidine analogs, which can be used to replace intravenous fluoropyrimidine, as well as the addition of new medications like oxaliplatin and docetaxel, which have been proven to be effective in treating patients with advanced disease, are among the significant developments in recent years. Targeted therapies have significantly changed how some cancers are treated, and even though they are still being tested in advanced, early-stage gastric cancer, it is likely that these drugs will continue to be created and researched in conjunction with chemotherapy. Advanced gastrointestinal cancer is increasingly being treated with a molecular focus. Metastatic gastroesophageal (GEJ) cancer routinely undergoes molecular profiling for HER2 and PD-L1 status, and expanded RAS and BRAF assays can predict the effectiveness of trastuzumab (a HER2-targeted therapy) and pembrolizumab (an anti-PD-1 therapy) in treating the disease. therapy that targets the epidermal growth factor receptor (EGFR). For metastatic colorectal cancer and pembrolizumab (all advanced gastrointestinal cancers), testing for mismatch repair (MMR) or microsatellite instability (MSI) is common to determine whether nivolumab with or without ipilimumab is beneficial.

Report Highlights

Advanced/Metastatic Gastrointestinal Cancer - Current Market Trends

Advanced/Metastatic Gastrointestinal Cancer - Current & Forecasted Cases across the G8 Countries

Advanced/Metastatic Gastrointestinal Cancer - Market Opportunities and Sales Potential for Agents

Advanced/Metastatic Gastrointestinal Cancer - Patient-based Market Forecast to 2035

Advanced/Metastatic Gastrointestinal Cancer - Untapped Business Opportunities

Advanced/Metastatic Gastrointestinal Cancer - Product Positioning Vis-a-vis Competitors' Products

Advanced/Metastatic Gastrointestinal Cancer - KOLs Insight